Insulet Co. (NASDAQ:PODD) – Investment analysts at William Blair reduced their Q4 2019 earnings per share estimates for shares of Insulet in a report released on Wednesday, November 6th. William Blair analyst M. Kaczor now expects that the medical instruments supplier will post earnings per share of $0.09 for the quarter, down from their prior estimate of $0.10. William Blair also issued estimates for Insulet’s Q3 2020 earnings at $0.19 EPS, Q4 2020 earnings at $0.28 EPS and Q1 2021 earnings at $0.13 EPS.

Several other equities research analysts have also recently weighed in on PODD. ValuEngine cut Insulet from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Stifel Nicolaus started coverage on Insulet in a report on Tuesday, October 22nd. They issued a “hold” rating and a $163.00 price objective for the company. Canaccord Genuity cut Insulet from a “buy” rating to a “hold” rating and increased their price objective for the stock from $135.00 to $145.00 in a report on Friday, October 18th. Robert W. Baird increased their price objective on Insulet from $165.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Svb Leerink increased their price objective on Insulet from $160.00 to $185.00 and gave the stock an “outperform” rating in a report on Tuesday, September 24th. Ten investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Insulet presently has a consensus rating of “Hold” and a consensus price target of $151.71.

Shares of Insulet stock opened at $169.46 on Friday. Insulet has a 12 month low of $70.80 and a 12 month high of $171.96. The company has a current ratio of 4.72, a quick ratio of 3.91 and a debt-to-equity ratio of 2.43. The business’s 50-day moving average price is $154.75 and its 200-day moving average price is $130.77. The firm has a market capitalization of $8.73 billion, a PE ratio of 3,389.20 and a beta of 0.96.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $192.12 million for the quarter, compared to the consensus estimate of $179.50 million. Insulet had a net margin of 2.38% and a return on equity of 9.46%. Insulet’s revenue for the quarter was up 27.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.03 earnings per share.

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Insulet by 0.5% during the second quarter. Vanguard Group Inc. now owns 5,284,289 shares of the medical instruments supplier’s stock valued at $630,838,000 after buying an additional 24,197 shares during the last quarter. William Blair Investment Management LLC raised its stake in Insulet by 8.8% during the second quarter. William Blair Investment Management LLC now owns 2,334,135 shares of the medical instruments supplier’s stock valued at $278,649,000 after buying an additional 189,147 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Insulet by 5.8% during the second quarter. JPMorgan Chase & Co. now owns 1,619,136 shares of the medical instruments supplier’s stock valued at $188,808,000 after buying an additional 88,440 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in Insulet during the second quarter valued at $87,481,000. Finally, Eagle Asset Management Inc. raised its stake in Insulet by 86.3% during the third quarter. Eagle Asset Management Inc. now owns 709,266 shares of the medical instruments supplier’s stock valued at $116,979,000 after buying an additional 328,620 shares during the last quarter.

In other Insulet news, SVP Michael P. Spears sold 4,153 shares of Insulet stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.12, for a total transaction of $606,836.36. Following the completion of the transaction, the senior vice president now owns 22,626 shares in the company, valued at $3,306,111.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Shacey Petrovic sold 649 shares of Insulet stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $152.40, for a total value of $98,907.60. The disclosure for this sale can be found here. Insiders have sold 5,491 shares of company stock valued at $806,124 in the last quarter. 3.50% of the stock is owned by company insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Read More: Day Trading – Risk Worth the Reward?

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.